Neural Stem Cell‐Derived Extracellular Vesicles Improve CNS Delivery and Therapeutic Efficacy of Antisense Oligonucleotide in Amyotrophic Lateral Sclerosis
Journal of Extracellular Vesicles · 2026
DOI: 10.1002/jev2.70370 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Extracellular Vesicles, 2026. Verfasst von Yaochao Zheng und 8 weiteren Autor:innen. Beteiligte Einrichtung: Regenerative Bioscience Center, Department of Animal and Dairy Science, College of agricultural and environmental sciences, University of Georgia, At…. Hauptthemen laut MEDLINE: Amyotrophic Lateral Sclerosis, Extracellular Vesicles, Oligonucleotides, Antisense, Neural Stem Cells. Die Arbeit nennt 96 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIA NIH HHS, Department of Defense, NIH HHS.
Abstract (Originalsprache)
Antisense oligonucleotides (ASOs) hold clinical promise for the treatment of neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS). Yet, their efficacy is constrained by the need for invasive delivery, poor central nervous system (CNS) penetration, inefficient cellular uptake and rapid clearance. Here, we developed neural stem cell‐derived extracellular vesicles (NSC‐EVs) as natural carriers to enhance CNS targeting and therapeutic efficacy of ASO‐based treatments for ALS. Using a passive loading method, therapeutic ASOs were efficiently associated with NSC‐EVs (NSC‐EV‐ASO). Compared with free ASOs, NSC‐EVs‐ ASOs exhibited markedly enhanced neuronal uptake in vitro and increased CNS accumulation and neuronal localization in vivo following intracerebroventricular, intranasal, or intravenous administration. Functionally, NSC‐EV‐ASOs reduced the mutant SOD1 protein expression and the pathogenic hexanucleotide repeats in the C9orf72 loci in ALS cellular models. In the ALS mouse model, intranasal administration of NSC‐EV‐ASOs more efficiently delayed disease onset, improved motor performance, preserved motor neurons and attenuated astrocyte activation during the study period compared with free ASOs. These findings provide proof‐of‐concept evidence supporting the potential of NSC‐EV as a promising platform that not only enhances CNS delivery of ASOs but also contributes to overall therapeutic activity, offering a synergistic strategy to advance nucleic acid therapeutics for ALS and potentially other neurological diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Regenerative Bioscience Center, Department of Animal and Dairy Science, College of agricultural and environmental sciences, University of Georgia, Athens, Georgia, USA.
- Department of Chemistry, University of Georgia, Athens, Georgia, USA.
- Department of Cell Biology, Emory University, Atlanta, Georgia, USA.
ORCID-Profile: Yaochao Zheng, Taylor Jade Ellison, Robert Garrard, Jin Xie, Jie Jiang, Yao Yao
Förderung
- NIA NIH HHS
- Department of Defense
- NIH HHS
- U.S. Department of Defense
- National Science Foundation
- National Institutes of Health
Zitieren
APA
Zheng, Y., Ellison, T. J., Garrard, R., Gao, J., Lai, X., Lan, L., Xie, J., Jiang, J., & Yao, Y. (2026). Neural Stem Cell‐Derived Extracellular Vesicles Improve CNS Delivery and Therapeutic Efficacy of Antisense Oligonucleotide in Amyotrophic Lateral Sclerosis. Journal of Extracellular Vesicles. https://doi.org/10.1002/jev2.70370
Vancouver
Zheng Y, Ellison TJ, Garrard R, Gao J, Lai X, Lan L, et al. Neural Stem Cell‐Derived Extracellular Vesicles Improve CNS Delivery and Therapeutic Efficacy of Antisense Oligonucleotide in Amyotrophic Lateral Sclerosis. Journal of Extracellular Vesicles. 2026. doi:10.1002/jev2.70370
BibTeX
@article{Zheng2026,
author = {Zheng, Yaochao and Ellison, Taylor Jade and Garrard, Robert and Gao, Jinghui and Lai, Xinning and Lan, Lin and Xie, Jin and Jiang, Jie and Yao, Yao},
title = {Neural Stem Cell‐Derived Extracellular Vesicles Improve CNS Delivery and Therapeutic Efficacy of Antisense Oligonucleotide in Amyotrophic Lateral Sclerosis},
journal = {Journal of Extracellular Vesicles},
year = {2026},
doi = {10.1002/jev2.70370}
}
EUVIMED